News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Competitive Technologies, Inc. (CTCC) Selected to Provide Pain Care Training to U.S. Military Personnel



10/17/2013 12:26:13 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FAIRFIELD, Conn., Oct. 15, 2013 /PRNewswire/ -- In a pain care skills training for military healthcare providers, technicians, policy makers and program managers in Portsmouth, Virginia, Competitive Technologies, Inc., (OTCQX: CTTC) (CTI) was selected as one of the pain care training providers to our Nation's military personnel. CTI's flagship 510-K cleared and CE-marked medical device, Calmare® was highlighted as a promising pain management device of choice.

"This military venue afforded CTI a unique opportunity to broaden Calmare's footprint within the military providers' and policy makers' circles to demonstrate the benefits of using our medical device," said CTI President & CEO Conrad Mir. "We strongly believe that the Calmare biophysical approach provides a viable alternative to the current standard of prescription drugs and opiates for patients suffering from various types of pain."

Calmare Use in the U.S. Military

The U.S. military is one of the largest providers of Calmare therapy in the world. The Calmare device is offered and available at medical centers and hospitals in all branches of service. Military providers use Calmare to treat an assortment of chronic neuropathic pain modalities including failed back surgery syndrome (FBSS), sciatic and lumbar pain, phantom limb syndrome, pudendal pain, post-herpetic neuralgia (PHN), post-surgical neuropathic pain, brachial plexus neuropathy, lower back pain (LBP), complex regional pain syndrome (CRPS or RSD), and cancer-related pain.

About the Company

Competitive Technologies Inc., (CTI) is a biotechnology company developing and commercializing innovative products and technologies. CTI is the licensed distributor of the non-invasive Calmare® pain therapy medical device, which incorporates the biophysical "Scrambler Therapy"® technology developed to treat neuropathic and cancer-derived pain by Professor Giuseppe Marineo.

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES